Dr. Mauro Discusses Drug Adherence Among CML Patients

MICHAEL MAURO, MD

Wednesday, February 25, 2015

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don’t adhere to their medication.

Mauro says once the disease has been treated, there are minimal symptoms. However, the therapies used to treat CML can lead to chronic low-grade adverse events. Since CML treatment is indefinite, this can be challenging for patients to deal with, Mauro says.â€‹

Discussions >>

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.

Related Videos

Challenges In AML Treatment

By: Pinkal Desai, MD

Expert Identifies Potential Biomarkers for Hairy Cell Leukemia

By: James Blachly, MD

Measurable Residual Disease's Role in the Relapse Setting

By: Frahad Ravandi-Kashani, MD